

**REQUEST FOR CONTINUED EXAMINATION
(RCE) TRANSMITTAL**

Subsection (b) of 35 U.S.C. § 132, effective on May 29, 2000, provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

<i>Application No.:</i>	10/024,858
<i>Filing Date:</i>	December 18, 2001
<i>First Named Inventor:</i>	Graham Leonard
<i>Group Art Unit:</i>	1615
<i>Examiner:</i>	H. Sheikh
<i>Attorney Docket No.:</i>	P31220X2C2

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the
U.S. Patent and Trademark Office on the date shown below.

Theresa M. Munro

Type Name of Person faxing this document

November 22, 2005

Signature

Data

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000, applicant may wish to consider filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Final Rule, 65 Fed. Reg. 50092 (Aug. 16, 2000); Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000) 1233 Off. Gaz. Pat. Office 47 (April 11, 2000), which established RCE practice.

1. Submission required under 37 C.F.R. § 1.114

- a. Previously submitted

 - i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on _____
(Any unentered amendment(s) referred to above will be entered)
 - ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed on _____
 - iii. Other _____

b. Enclosed

 - i. Amendment/Rcply 3 pages
 - ii. Affadavit(s)/Declaration(s) _____ pages
 - iii. Information Disclosure Statement (IDS) 1 page
 - iv. Form PTO 1449 1 pg. & 3 References
 - v. Return Receipt Postcard (MPEP 503) (*specifically itemized*)
 - vi. Other _____

2. Miscellaneous

- a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(l) required)

b. Other _____

- a. The Director is hereby authorized to charge the following fees or credit any overpayments, to Deposit Account No. 19-2570

- General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(c)(3))

- i. RCE fee required under 37 C.F.R. § 1.17(e). \$790.00
ii. () Month Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
iii. Additional Fees

iv. Total Fee to be charged to Deposit Account 19-2570 \$790.00

CORRESPONDENCE ADDRESS

Address GLAXOSMITHKLINE
Corporate Intellectual Property – UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Telephone (610) 270-5023 **Faxsimile** (610) 270-5090

n:\wjd\paroxetine\P312220 Paxil CR\RCE-3.doc

RESPECTFULLY SUBMITTED,

Signature Wayne
NAME Wayne J. Dustman

Registration No. 33,870

11/23/2005 AKELI 00000001 192570 10024858